Clinical CDK2 Inhibitors: Trends to Selectivity and Efficacy

Recent Pat Anticancer Drug Discov. 2022;18(2):102-107. doi: 10.2174/1574892817666220617091700.

Polina V Rusina^{1

2}, Alexey A Lisov^{1

2}, Alexandra A Denisova³, Erik R Gandalipov⁴, Fedor N Novikov^{2

5}, Alexander A Shtil^{1

6}

¹ Department of Chemistry, Lomonosov Moscow State University, 1/3 Leninskie Gory, 119991, Moscow, Russian Federation.
² Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Avenue, 119991, Moscow, Russian Federation.
³ Faculty of Bioengineering and Bioinformatics, Moscow State University, 1-73 Leninskie Gory, 119234, Moscow, Russian Federation.
⁴ International Institute of Solution Chemistry and Advanced Materials Technologies, ITMO University, 9 Lomonosov Street, 191002, Saint-Petersburg, Russian Federation.
⁵ National Research University `Higher School of Economics\', 20 Myasnitskaya Street, 101000, Moscow, Russian Federation.
⁶ Blokhin National Medical Research Center of Oncology, 24 Kashirskoye shosse, 115478, Moscow, Russian Federation.

No abstract available

Keywords: CDK2; cancer; catalytic domain.; clinical trials; inhibitors; serine-threonine protein kinase.

MeSH terms